completed2020-07-01D series

Indacaterol/Mometason

Brand: Atectura® Breezhaler®
Manufacturer: Novartis Pharma GmbH

G-BA action

final resolution

2020-09-03

Arzneimittel-Richtlinie/Anlage XII und Anlage IX: Festbetragsgruppenbildung Kombinationen von Glucocorticoiden mit langwirksamen Beta2-Sympathomimetika, Gruppe 1, in Stufe 3

Evidence-checked summary

The G-BA issued a final resolution on 2020-09-03. The official page states that it took effect as follows: 03.09.2020. The page lists Arzneimittel-Richtlinie, Anlage IX: Festbetragsgruppenbildung, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

0 hearing

No official oral hearing is attached to this case.

IQWiG comparison

Assessment record versus G-BA action

0 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.

G-BA decisions

Distinct actions and documents

1 decision

2020-09-03

final resolution

Arzneimittel-Richtlinie/Anlage XII und Anlage IX: Festbetragsgruppenbildung Kombinationen von Glucocorticoiden mit langwirksamen Beta2-Sympathomimetika, Gruppe 1, in Stufe 3

2 official documents · 3 cited claims

Open decision →

Official sources

Case document package

3 source

official case pageOfficial G-BA case pageOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗

Generic graph relations · 1

HAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII und Anlage IX: Festbetragsgruppenbildung Kombinationen von Glucocorticoiden mit langwirksamen Beta2-Sympathomimetika, Gruppe 1, in Stufe 3